Eli Lilly launches Mounjaro in India following drug regulator approval, targeting diabetes and weight-loss in a rapidly ...

Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP and GLP-1 receptors, which are natural incretin hormones, the company stated.

Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from country's drug ...

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Jim Cramer recently talked about the market selloff and how years of profits are lost within days when panic hits the market: ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...